- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CT medium circulates in blood pool
Photogen Technologies is testing a contrast agent that stays in the vascular system for at least 20 minutes with little diffusion outside. If tests pan out, the experimental agent, which has been tested only in animals, could serve as both a perfusion
Photogen Technologies is testing a contrast agent that stays in the vascular system for at least 20 minutes with little diffusion outside. If tests pan out, the experimental agent, which has been tested only in animals, could serve as both a perfusion and blood pool agent. Preclinical studies indicate that the proprietary agent, called PH-50, has potential in coronary, cardiac, great vessel, and renal arterial CT. Through luminaries at Stanford University, the New Hope, PA, company also hopes to explore the use of this agent as a means for imaging soft noncalcified plaques in coronary arteries, where its presence is a marker of likelihood to rupture and cause sudden death.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
